TY - JOUR
T1 - Growth in children with chronic renal failure on intermittent versus daily calcitriol
AU - Schmitt, Claus Peter
AU - Ardissino, Gianluigi
AU - Testa, Sara
AU - Claris-Appiani, Aldo
AU - Mehls, Otto
AU - Michelis, K.
AU - Sallay, P.
AU - Drozdz, D.
AU - Zurowska, A.
AU - Perfumo, F.
AU - Berg, U.
AU - Tirelli, S.
AU - Murer, M. L.
AU - Dusek, J.
AU - Picca, S.
AU - Wigger, M.
AU - Fischbach, M.
AU - Bonaudo, R.
AU - Neuhaus, T.
PY - 2003/5/1
Y1 - 2003/5/1
N2 - Calcitriol (C) treatment strategies for secondary hyperparathyroidism remain controversial regarding efficacy and safety. In children, intermittent C administration has been suspected of impairing body growth. In a prospective, randomized multicenter study, we compared the effect of daily versus twice weekly C on plasma intact parathyroid hormone (iPTH) levels and growth in 24 prepubertal children with chronic renal insufficiency (mean creatinine clearance 20±9 ml/min per 1.73 m2). After a 3-week washout period, the patients were randomly assigned to 10 ng/kg per day or 35 ng/kg twice a week oral C. The C dose was kept constant for 2 months and could then be adapted to maintain an iPTH target range of 140-280 pg/ml. Median (range baseline iPTH levels were 567 (114-1209) pg/ml in the daily and 332 (93-614) pg/ml in the intermittent treatment group (P=NS). After 12 months, iPTH had decreased to 255 (85-710) and 179 (51-443) pg/ml (P
AB - Calcitriol (C) treatment strategies for secondary hyperparathyroidism remain controversial regarding efficacy and safety. In children, intermittent C administration has been suspected of impairing body growth. In a prospective, randomized multicenter study, we compared the effect of daily versus twice weekly C on plasma intact parathyroid hormone (iPTH) levels and growth in 24 prepubertal children with chronic renal insufficiency (mean creatinine clearance 20±9 ml/min per 1.73 m2). After a 3-week washout period, the patients were randomly assigned to 10 ng/kg per day or 35 ng/kg twice a week oral C. The C dose was kept constant for 2 months and could then be adapted to maintain an iPTH target range of 140-280 pg/ml. Median (range baseline iPTH levels were 567 (114-1209) pg/ml in the daily and 332 (93-614) pg/ml in the intermittent treatment group (P=NS). After 12 months, iPTH had decreased to 255 (85-710) and 179 (51-443) pg/ml (P
KW - Chronic renal failure
KW - Growth
KW - Intermittent calcitriol
KW - Secondary hyperparathyroidism
UR - http://www.scopus.com/inward/record.url?scp=10744224831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744224831&partnerID=8YFLogxK
M3 - Article
C2 - 12687466
AN - SCOPUS:10744224831
VL - 18
SP - 440
EP - 444
JO - Pediatric Nephrology
JF - Pediatric Nephrology
SN - 0931-041X
IS - 5
ER -